Tariff-related Litigation Update
Explore the latest IEEPA tariff developments and legal challenges, including executive orders on fentanyl tariffs and reciprocal duties affecting global MedTech trade.
Resource Library
Access our full library of guidance, white papers, and other resources developed by and for the medical technology industry.
Filter By:
Topics
No results found
Resource Type
No results found
Week 6: Regulatory Shifts, Tariff Action & Industry Feedback
USTR proposes new China tariffs; FDA, CMS, and White House actions could reshape MedTech—member input needed by June 10.
AdvaMed Response to House Privacy Working Group RFI
AdvaMed calls for federal privacy laws that reflect how medical devices use patient data differently from consumer health tools.
AdvaMed Comments to DOJ Anticompetitive Regulations RFC
AdvaMed urges DOJ to remove outdated rules that block medtech innovation and limit access to lifesaving technology.
Week 5: Trade Rules, Tariffs & Congressional Engagement
White House tariff actions, DOJ and CMS RFIs, and USTR investigations headline Week 5—member feedback needed this month.
Listen to AdvaMed®'s Podcast
Brought to you by AdvaMed®, Medtech POV with Scott Whitaker is a podcast that covers the intersection of medtech and policy from every perspective.
Rapid Response Weekly Updates – Week 4
Scott Whitaker’s Senate testimony, drug pricing EO, and updates on key RFIs drive this week’s momentum for MedTech advocacy.
Executive Overview_Kennedy v. Braidwood Management, Inc.
The U.S. Supreme Court is reviewing Braidwood Management v. Becerra, a high-stakes case challenging the authority of the U.S. Preventive Services Task Force (USPSTF) under the Affordable Care Act. At…
AdvaMed Comments to OMB Deregulation RFI
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.